New funds back Axelar's IGF-1 receptor inhibitor in NSCLC
This article was originally published in Scrip
Executive Summary
Axelar, a privately-held Swedish biotech company, has raised SEK123 million (€13.7 million) to complete a Phase II programme of its insulin-like growth factor-1 (IGF-1) inhibitor AXL1717 in patients suffering from non-small cell lung cancer (NSCLC).